



Cancer Immunotherapy: Drugs, Predictive Markers, Successes and Failures

Guest Editor:

Dr. Emma Shtivelman
Chief Scientist at Cancer
Commons, Los Altos, CA, USA

Deadline for manuscript
submissions:
closed (15 September 2020)

Message from the Guest Editor

Dear Colleagues,

The immunotherapy of cancer has advanced tremendously in the last decade, transforming the standard of care for many cancer types. This Issue aims to provide reviews of approved and investigational immune drugs in different categories: immune checkpoint drugs, adoptive cell transfer, immune cytokines, drugs activating the innate immune system and combinations thereof, or combinations with chemotherapy or targeted drugs. Some drugs in each category already have a proven track record in cancer treatment, while others are lagging behind for various reasons. The problems slowing down the progress could be ascribed to the lack of predictive markers of response to immune interventions; the relative prevalence of immune-cold cancers in general; and lack of a strong scientific rationale for the design of trials with drug combinations.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. David Alan Rizzieri

1. Novant Health Cancer
Institute, Winston-Salem, NC
27103, USA
2. Division of Hematologic
Malignancies and Cellular
Therapy, Duke University,
Durham, NC 27710, USA

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, ‘omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

Journal Rank: JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Journal of Personalized Medicine
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/jpm
jpm@mdpi.com
[X@JPM_MDPI](https://twitter.com/JPM_MDPI)